Emcure Pharma Q2 FY27 Earnings Call — Analysis (NSE: EMCURE)

Emcure delivered 24% revenue growth and 31% EBITDA growth in Q2FY27, raising its full-year FY27 revenue guidance to above 20% on broad-based international traction and domestic recovery.

6 Nov 2026 · Analysis by Alpha Inflection

Result quality: stable — Steady quarter. Management sentiment: optimistic.

The take

Q2FY27 Revenue from Operations ₹2,820 Cr ( +24.3% YoY ) . Guidance raised — FY27 fy27 revenue growth revised gui… exceed 20% . But missed . New story: Domestic recovery and Zuventus turnaround .

Results

Revenue grew 24.3% YoY to ₹2,820 Cr with EBITDA margins expanding 100 bps YoY to 20.4%, while PAT increased 29% to ₹325 Cr.

Financial highlights

Guidance

Management raised full-year FY27 revenue growth guidance to exceed 20% (up from mid-teens) and expects EBITDA margin expansion at the upper end of 75-100 bps.

What management committed to

• [Emcure] expects full-year FY27 revenue growth to exceed 20%. — exceed 20%, FY27
• [Emcure] expects FY27 EBITDA margin expansion to be at the upper end of the 75 to 100 basis points range. — upper end of 75 to 100 bps, FY27

Key themes

Guidance upgrade driven by international momentum

How the narrative shifted

• Domestic recovery and Zuventus turnaround: Management presented the amalgamation approval and sequential improvement of Zuventus as evidence that the stability and consolidation phases are complete, allowing the acceleration phase to begin.
• International scale-up as growth engine: Strong performance across Europe, Canada, and ROW, combined with new approvals (amphotericin in Brazil, Mexico) and the lenacapavir filing, drove the decision to raise the full-year revenue guidance to >20%.
• Biosimilars and Gennova integration: R&D investments and pipeline were discussed, with biosimilars emerging in context of approvals (bevacizumab for wet AMD), but Gennova not highlighted prominently beyond the amalgamation note.
• In-licensing and portfolio complementarity: In-licensing was noted as contributing a 'high teens' share of domestic revenue, but less prominent as a narrative driver compared to the organic and international growth story.
• Margin resilience despite gross margin mix pressure: Management raised the margin expansion guidance to the upper end of the range, highlighting operating leverage and cost controls as key drivers, while acknowledging rising input costs and freight.
• Currency tailwind and geopolitical resilience: The currency tailwind is now framed more neutrally as part of a hedge against rising input costs, moving it from a pure tailwind to a stabilizer.
• Operating leverage as margin driver: Management explicitly guided that SG&A growth will be slower than revenue growth, making operating leverage a specific and explicit tool for margin expansion.
• GLP-1 and obesity market shaping: Management discussed the significant contribution of GLP-1 brands to IPM growth (4-5% of market) and Emcure's long-term positioning with semaglutide and Poviztra, shaping a long-term narrative.

Operational commentary

• Board approved the amalgamation of wholly owned subsidiaries Zuventus Healthcare and Emcutix Biopharmaceuticals into Emcure on October 12, 2026, aimed at back-end and corporate operational synergies.
• Received over 20 product approvals in Q2FY27, including liposomal amphotericin B in Brazil and Mexico, and bevacizumab for wet AMD in India.
• Filed regulatory dossiers for lenacapavir with the WHO and US FDA for RoW markets, following positive Subject Expert Committee recommendation in India for PrEP indication.
• Zuventus operations stabilized with domestic organic growth rising to 10% YoY in Q2FY27 from 6% YoY in Q1FY27.
• Europe growth was driven by base portfolio gains and scale-up of liposomal amphotericin B, with treprostinil identified as the next key complex product launch.
• Field force count maintained at 4,100–4,200 reps with growth being driven by rep productivity rather than headcount expansion.

Analyst Q&A

• Q. What is the contribution and market outlook for liposomal amphotericin B in Europe and other international markets?

  Management clarified that liposomal amphotericin B is less than 10% of international sales with penetration in only ~50% of targeted European countries (about 20 countries remaining to enter), and commercial launches in Latin America/RoW markets are scheduled for 2HFY27.

• Q. When can domestic organic growth, particularly from Zuventus, align with industry market growth?

  Management indicated that following last year's field force attrition, Zuventus has stabilized and consolidated; domestic business organic growth should align with or exceed Indian Pharmaceutical Market growth exit FY27, finishing in the low-teens for the full year.

• Q. Can management break out the exact revenue contribution and growth rate for the Zuventus business and OTC segment?

  Management declined to break out Zuventus growth figures separately beyond stating it comprises ~25% of revenues, and declined to quantify OTC revenue share, noting it is still early-stage and scaling up.

• Q. What is the status of filing semaglutide in Canada and timeline for supplying Quebec partner Dr. Reddy's?

  Management stated semaglutide Canadian filing will happen in the next few months within FY27, and supplies for Dr. Reddy's in Quebec will commence once final partner supply schedules are confirmed.

View source

Research and educational content only. Not investment advice.